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Hemosiderotic ﬁbrohistiocytic lipomatous tumors are rare neoplasms that were ﬁrst
described in 2000. Initially considered a benign lipotamous lesion of the soft tissues, nowa-
days they are considered to be a locally aggressive tumor. They occur mainly in the foot and
ankle  of women in their ﬁfth and sixth decades, although they may be found in any place
in  the lower limbs and, more rarely, in other parts of the body. Histologically, hemosiderotic
ﬁbrohistiocytic lipomatous tumors consist of a mixture of mature adipose tissue, fusiform
cell  fascicles, macrophages that often contain cytoplasmic hemosiderin, mononuclear
inﬂammatory inﬁltrate, and stroma that may be focally myxoid. Local recurrence is observed
in  nearly one-third of all cases. There is no consensus in the literature whether this tumor
is  a part of a spectrum that comprises pleomorphic hyalinizing angiectatic tumors and
myxoinﬂammatory ﬁbroblastic malignant tumors, or if it is an independent entity.
The authors report a case of a neoplasia after a diagnosis of a hemosiderotic ﬁbrohistio-
cytic lipomatous tumor in a 38-year-old woman, with two recurrences and later sarcomatous
transformation. An immunohistochemical study indicated myoﬁbroblastic differentiation
of  a malignant neoplasm. To the best of the authors’ knowledge, there are only few reported
cases of malignant transformation in hemosiderotic ﬁbrohistiocytic lipomatous tumors.©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Please cite this article in press as: Etchebehere RM, et al. Sarcomatous transformation of a hemosiderotic ﬁbrohistiocytic lipomatous tumor: a
case report. Rev Bras Ortop. 2016. http://dx.doi.org/10.1016/j.rboe.2016.11.002
 Work performed in the Hospital de Clínicas, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brazil.
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255-4971/© 2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora Ltda. This is an open access article
nder  the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Transformac¸ão  sarcomatosa  de  tumor  lipomatoso  ﬁbrohistiocítico
hemosiderótico:  relato  de  caso
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r  e  s  u  m  o
Os tumores lipomatosos ﬁbrohistiocíticos hemosideróticos são neoplasias raras que foram
descritas pela primeira vez no ano 2000. Inicialmente considerada uma  lesão lipomatosa
benigna dos tecidos moles, atualmente é considerado um tumor localmente agressivo. Estas
lesões ocorrem principalmente no pé e no tornozelo das mulheres na quinta e sexta décadas
de  vida, embora possam ser encontrados em qualquer lugar nos membros inferiores e, mais
raramente, em outras partes do corpo. Histologicamente, tumores lipomatosos ﬁbrohisti-
ocíticos hemosideróticos são formados por uma combinac¸ão de tecido adiposo maduro,
fascículos de células fusiformes, macrófagos que contêm frequentemente hemosiderina
citoplasmática, inﬁltrado inﬂamatório mononuclear e estroma, que pode ser focalmente
mixoide. Há recidiva local em quase um terc¸o dos casos. Não existe consenso na literatura
se  este tumor faz parte de um espectro que envolve os tumores angiectásicos hialinizantes
pleomórﬁcos e os tumores ﬁbroblásticos mixoinﬂamatórios malignos, ou se conﬁgura uma
entidade independente.
Relatamos um caso de uma neoplasia após o diagnóstico de tumor lipomatoso ﬁbro-
histiocítico hemosiderótico em uma mulher de 38 anos, com duas recorrências e posterior
transformac¸ão  sarcomatosa. Um estudo imuno-histoquímico indicou diferenciac¸ão mioﬁ-
broblástica de uma neoplasia maligna. Para nosso conhecimento, há apenas poucos
casos  relatados de uma transformac¸ão maligna em tumores lipomatosos ﬁbrohistiocíticos
hemosideróticos.
©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://
neous tissues of the distal third of the left thigh, associated
with an osteolytic lesion in the cortical region of the mid-Introduction
Hemosiderotic ﬁbrohistiocytic lipomatous tumor (HFLT) is a
rare neoplasm that was initially thought to be a reactive pro-
cess secondary to trauma or an excessive tissue response to
chronic venous stasis, which would stimulate the prolifera-
tion of elements seen in the lesion.1 Browne and Fletcher
(2006) published a classic review of this tumor in which deﬁned
the clinical and histological characteristics.2 Initially, HFLT
was believed to be a benign lipomatous neoplasm. The con-
temporary understanding is that HFLT is an unencapsulated,
locally aggressive neoplasm that is composed of adipocytes,
hemosiderin-laden spindle cells and macrophages, as well as
scattered chronic inﬂammatory cells. The commonest site for
HFLT is the dorsum of the foot, followed by other ankle and
foot sites, the dorsum of the hand, and, ﬁnally, the calf, thigh,
and cheek. HFLT is most frequently found in women in their
ﬁfth or sixth decade of life.1–6
Radiologic images of the lesion reveal adipose tissue, often
with septation, and features mimicking lipoma or low-grade
sarcoma.7 Clinical and pathological features of HFLT are sim-
ilar to those of pleomorphic hyalinizing angiectatic tumor
(PHAT) and myxoinﬂammatory ﬁbroblastic malignant tumor
(MIFS), leading authors to speculate that HFLT may be a part
of a spectrum involving these two other tumor types.8–10
HFLT does not produce metastases and is of uncertain lineagePlease cite this article in press as: Etchebehere RM, et al. Sarcomatous tra
case report. Rev Bras Ortop. 2016. http://dx.doi.org/10.1016/j.rboe.2016.11.0
according to the soft-tissue tumor classiﬁcation system of the
World Health Organization.1creativecommons.org/licenses/by-nc-nd/4.0/).
There are few reports of the malignant transformation of
HFLT into MIFS.9,10 Herein, we report a published case of a
lesion that had previously been diagnosed, according to its
morphological and by immunohistochemical (IHC) features,
as HFLT.8 The lesion recurred twice and later showed malig-
nant transformation to a low-grade unclassiﬁed pleomorphic
sarcoma, with an IHC study suggesting myoﬁbroblastic differ-
entiation.
Case  report
This case report was approved by the Ethics Committee at a
tertiary public hospital. A 38-year-old female patient came to
our clinic in December of 2010. She complained of a painful
lesion in the back area of her left thigh, in the vicinity of prior
tumor surgical resections (performed in September of 2006
and January of 2008). Previous resections led to a diagnosis
of HFLT, based on morphological examination and comple-
mentary IHC study. The prior biopsies were reviewed, and the
diagnosis was maintained. This case of HFLT has been previ-
ously reported in the literature.8
Magnetic resonance imaging showed a heterogeneous
lesion with expansive growth and enhancement. Imaging
suggested compromise to the muscle groups and subcuta-nsformation of a hemosiderotic ﬁbrohistiocytic lipomatous tumor: a
02
dle third of the left femur. Tumor resection was performed,
and two roughly ovoid fragments of black-yellow and elastic
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Fig. 1 – (A) Hemosiderotic ﬁbrohistiocytic lipomatous tumors (HFLT) area (hematoxylin–eosin – HE, 100×); (B) malignant
transformation area of HFLT showing increased cellularity and nuclear pleomorphism (HE, 100×); (C) nuclear atypia in the
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ralignant transformation area of HFLT (HE, 400×).
issue were obtained for histological evaluation. Tissues had
emorrhagic foci jointly measuring 22 cm × 18 cm × 11 cm and
eighing 485 g.
Microscopy showed an inﬁltrative, pleomorphic malignant
eoplasm, with irregular edges in the soft tissues and vari-
ble cellularity. The neoplasm was comprised of round, oval,
nd fusiform cells, with hyperchromatic nuclei, sometimes
izarre and eosinophilic cytoplasms, and rare mitotic ﬁgures,
ompatible with sarcomatous transformation of the HFLT. We
lso noted areas with mature and often histiocytic adipose
issue containing hemosiderin (Fig. 1). This ﬁnding suggested
hat these were areas of a residual HFLT. No necrotic foci were
isible.
On IHC analysis, the lesion was focally positive for smooth
uscle actin and desmin, but negative for S100 protein
nd CD34, suggesting myoﬁbroblastic differentiation of the
arcomatous component. A cell proliferation index of approx-
mately 5% (Ki 67) was observed. Amputation was proposed
o the patient, who refused this treatment and underwent
hemotherapy and radiotherapy at other hospital.
iscussion
e  compared ﬁndings from the previous resections, which
ielded a diagnosis of HFLT, with the current morphology,2
hich exhibited malignant features. This comparison allowed
s to conclude that the lesion had undergone malignant trans-
ormation to a low-grade unclassiﬁed pleomorphic sarcoma,
ith IHC features suggesting myoﬁbroblastic differentiation.
he presence of areas with a benign pattern similar to the ini-
ial lesion intermixed with pleomorphic and inﬁltrative areas,
s well as the proliferative index, reinforced this conclusion.
Reports have described the presence of gene rearrange-
ents in tumors showing mixed features, which strongly
uggested a relationship of HFLT with PHAT and MIFS. Previous
uthors have concluded that HFLT, PHAT, and MIFS represent
orphologic variants of a single entity, in which only the later
as acquired the capacity to metastasize.3,8,9 One histologi-Please cite this article in press as: Etchebehere RM, et al. Sarcomatous tra
case report. Rev Bras Ortop. 2016. http://dx.doi.org/10.1016/j.rboe.2016.11.0
al study suggested that most, if not all, tumors diagnosed as
HATs might actually represent examples of MIFS with aber-
ant angiectatic hyalinized vessels. Furthermore, the vascular
hanges in PHAT may represent only a histologic pattern andnot a true neoplasm. Thus, MIFS and most cases of PHAT may
represent different morphologic manifestations of a single
entity.10
In this report, we  present a case of HFLT with malignant
transformation. The tumor retained areas similar to the origi-
nal tumor, reinforcing the possibility that this entity is part of
a spectrum of lesions with the potential for malignant evolu-
tion. After surgical resection of HFLT, patients should undergo
rigorous and regular follow-up because of the possibility of
sarcomatous transformation.
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